Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

被引:0
|
作者
Weinbergerova, Barbora [1 ,2 ]
Mayer, Jiri [1 ,2 ]
Kabut, Tomas [1 ,2 ]
Sperr, Wolfgang R. [3 ,4 ]
Stevkova, Jana [5 ]
Jonasova, Anna [6 ]
Cernan, Martin [7 ,8 ]
Herndlhofer, Susanne [3 ]
Oravcova, Iveta [9 ,10 ]
Sramek, Jiri [11 ]
Novak, Jan [12 ,13 ]
Stepanova, Radka [14 ]
Szotkowski, Tomas [7 ,8 ]
Drgona, Lubos [9 ,10 ]
Zak, Pavel [5 ]
Valent, Peter [3 ,4 ]
机构
[1] Masaryk Univ, Dept Internal Med Hematol & Oncol, Jihlavska 20, Brno 62500, Czech Republic
[2] Univ Hosp Brno, Jihlavska 20, Brno 62500, Czech Republic
[3] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[4] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Vienna, Austria
[5] Univ Hosp Hradec Kralove, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic
[6] Charles Univ Prague, Gen Hosp, Med Dept, Hematol, Prague, Czech Republic
[7] Palacky Univ Olomouc, Fac Med & Dent, Dept Hemato Oncol, Olomouc, Czech Republic
[8] Univ Hosp Olomouc, Olomouc, Czech Republic
[9] Comenius Univ, Dept Oncohematol, Bratislava, Slovakia
[10] Natl Canc Inst, Bratislava, Slovakia
[11] Univ Hosp Plzen, Dept Haematol & Oncol, Plzen, Czech Republic
[12] Charles Univ Prague, Fac Med 3, Dept Haematol, Prague, Czech Republic
[13] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic
[14] Masaryk Univ, Fac Med, Ctr Excellence CREAT, Brno, Czech Republic
关键词
acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine;
D O I
10.1111/bjh.19670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [2] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia
    Abbott, Diana
    Cherry, Evan
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Winters, Amanda
    Schowinsky, Jeffrey
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1466 - 1473
  • [3] Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
    Pratz, Keith W.
    DiNardo, Courtney D.
    Selleslag, Dominik
    Li, Junmin
    Yamamoto, Kazuhito
    Konopleva, Marina
    McDonald, Andrew
    Babu, Sunil
    Stevens, Don A.
    Kantarjian, Hagop M.
    Traina, Fabiola
    Venditti, Adriano
    Mayer, Jiri
    Montez, Melissa
    Ramsingh, Giridharan
    Jin, Huan
    Ainsworth, William
    Duan, Yinghui
    Svensson, Anders Erik
    Werner, Michael
    Potluri, Jalaja
    Jonas, Brian A.
    BLOOD, 2020, 136
  • [4] Low-dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
    Rong, Chunmeng
    Yang, Fang
    Chen, Yalu
    Wang, Ming
    Ai, Cheng
    Luo, Yuqing
    Gao, Panpan
    Weng, Yiqin
    Huang, Xiaguang
    Gu, Meier
    Huang, Weiping
    Xia, Yongming
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [5] Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis
    Venditti, Adriano
    Hou, Jing-Zhou
    Fenaux, Pierre
    Jonas, Brian A.
    Vrhovac, Radovan
    Montesinos, Pau
    Garcia, Jacqueline S.
    Rizzieri, David
    Thirman, Michael J.
    Kotey, Stanley
    Potluri, Jalaja
    Dhalla, Mazaher
    Pullarkat, Vinod
    BLOOD, 2023, 142
  • [6] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [7] Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Harris, Courtney E.
    Winer, Eric S.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, R. Coleman
    Copson, Kevin M.
    Charles, Anne
    Marty, Francisco
    Neuberg, Donna
    DeAngelo, Daniel J.
    Stone, Richard M.
    Luskin, Marlise R.
    Issa, Nicolas C.
    Garcia, Jacqueline S.
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1934 - 1941
  • [8] Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance
    Burke, Mary
    Sallman, David A.
    Denson, Ariel
    Nelson, Rebecca Jean
    Chan, Onyee
    Walker, Alison R.
    Padron, Eric
    Xie, Zhuoer
    Komrokji, Rami S.
    Lancet, Jeffrey
    Kuykendall, Andrew T.
    Tobon, Katherine
    Jain, Akriti Gupta
    Wang, Chen
    Al Ali, Najla H.
    BLOOD, 2023, 142
  • [9] Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
    Liang, Peiqi
    Xie, Yan
    Liu, Ziyi
    Wang, Dong
    Li, Qian
    Lu, Yin
    Xue, Shengli
    Wang, Ying
    Chen, Suning
    Wu, Deipei
    Fu, Jianhong
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1219 - 1226
  • [10] Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax plus hypomethylating agents
    Johnson, Isla M.
    Karrar, Omer
    Rana, Masooma
    Iftikhar, Moazah
    Chen, Sunny
    McCullough, Kristen
    Saliba, Antoine N.
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Litzow, Mark
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Hermann, Joerg
    Tefferi, Ayalew
    Gangat, Naseema
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1232 - 1237